Chirag Acharya

ORCID: 0000-0001-8767-5905
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Myeloma Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Lymphocytic Leukemia Research
  • Peptidase Inhibition and Analysis
  • Biochemical and Molecular Research
  • Calcium signaling and nucleotide metabolism
  • PARP inhibition in cancer therapy
  • Cancer therapeutics and mechanisms
  • Protein Degradation and Inhibitors
  • Nuclear Structure and Function
  • Research on Leishmaniasis Studies
  • T-cell and B-cell Immunology
  • Chemokine receptors and signaling
  • Cell Adhesion Molecules Research
  • Histone Deacetylase Inhibitors Research
  • Cancer-related Molecular Pathways
  • Immune Cell Function and Interaction
  • HIV/AIDS drug development and treatment
  • Acute Myeloid Leukemia Research
  • Immunotherapy and Immune Responses
  • Glycosylation and Glycoproteins Research
  • Chronic Myeloid Leukemia Treatments
  • Signaling Pathways in Disease
  • Bone health and treatments
  • RNA Interference and Gene Delivery

Dana-Farber Cancer Institute
2011-2024

Texas Tech University
2021

University of Mississippi Medical Center
2017-2018

Jackson Memorial Hospital
2017-2018

Harvard University
2013-2017

Purpose: We study CD38 levels in immunosuppressive CD4+CD25highFoxp3+ regulatory T cells (Treg) and further define immunomodulating effects of a therapeutic mAb isatuximab/SAR650984 multiple myeloma.Experimental Design: evaluated percentages CD38-expressing subsets Tregs from normal donors myeloma patients. Peripheral blood mononuclear (PBMC) were then treated with isatuximab or without lenalidomide pomalidomide to identify their impact on the percentage activity CD4+CD25- (Tcons)....

10.1158/1078-0432.ccr-16-3192 article EN Clinical Cancer Research 2017-03-02

Elevated inflammatory markers are associated with poor outcomes in various types of cancers; however, their clinical significance multiple myeloma (MM) have seldom been explored. This study investigated the prognostic relevance neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), and monocyte-to-lymphocyte (MLR) MM. Totally 559 MM patients were included this study. NLR, PLR MLR calculated from whole blood counts prior to therapy. Kaplan-Meier curves multivariate Cox...

10.18632/oncotarget.13320 article EN Oncotarget 2016-11-12

Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and a collection of multiple, genetically distinct subclones are present within the cell population. It not clear whether size clonal populations harboring unique cytogenetic abnormalities carry any additional prognostic value.We analyzed impact aberrations by fluorescence situ hybridization at different cutoff values cohort 333 patients with newly diagnosed 92 relapsed myeloma.We found nearly all...

10.1158/1078-0432.ccr-14-2576 article EN Clinical Cancer Research 2015-02-05

Abstract Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here novel c-Myc/miR-23b/Sp1 feed-forward loop with critical role in multiple myeloma (MM) and Waldenstrom’s macroglobulinemia (WM) cell growth survival. have found miR-23b to be downregulated MM WM cells especially the presence components tumor bone marrow milieu. Promoter methylation is one mechanism suppression myeloma. In gain-of-function studies using mimics-transfected...

10.1038/bcj.2015.106 article EN cc-by Blood Cancer Journal 2016-01-15

The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, APO866, has been previously shown to have antileukemic activity in preclinical models, but its cytotoxicity primary leukemia cells is frequently limited. success of current treatments reduced by the occurrence multidrug resistance, which, turn, mediated membrane transport proteins, such as P-glycoprotein-1 (Pgp). Here, we evaluated effects APO866 combination with Pgp inhibitors and studied mechanisms underlying interaction between...

10.1158/1078-0432.ccr-14-3023 article EN Clinical Cancer Research 2015-05-12

Abstract Purpose: Nicotinamide phosphoribosyltransferase (Nampt) regulates intracellular NAD+ pool and is highly expressed in a number of malignancies. FK866, selective inhibitor Nampt, depletes levels, thereby blocking cellular metabolism triggering sensitization to other drugs cell death. Here we characterized the antitumor effects Nampt inhibition Waldenström macroglobulinemia. Experimental Design: We investigated role MW cells using both mRNA protein expression analyses. have also used...

10.1158/1078-0432.ccr-16-0630 article EN Clinical Cancer Research 2016-06-11

// Meirong Zang 1, * , Dehui Zou Zhen Yu 1 Fei Li 4 Shuhua Yi Xiaofei Ai Xiaoqi Qin Xiaoyan Feng 3 Wen Zhou 2 Yan Xu Zengjun Mu Hao Weiwei Sui Shuhui Deng Chirag Acharya Yaozhong Zhao Kun Ru Lugui Qiu Gang An State Key Laboratory of Experimental Hematology, Institute Hematology & Blood Diseases Hospital, Chinese Academy Medical Science Peking Union College, Tianjin, China Cancer Research Institute, Carcinogenesis Ministry Health and Invasion Education, Central South University, Changsha,...

10.18632/oncotarget.5371 article EN Oncotarget 2015-09-17

Background: Black kidney transplant recipients have worse allograft outcomes compared to White recipients. The feature importance and interaction network analysis framework of machine learning random forest (RF) may provide an understanding RF structures design strategies prevent acute rejection among Methods: We conducted tree-based in United States from 2015 2019 the UNOS database using number nodes, accuracy decrease, gini times_a_root, p value, mean minimal depth. Feature was also...

10.3390/medicines8110066 article EN cc-by Medicines 2021-11-02
Coming Soon ...